Abstract:Funding Acknowledgements Type of funding sources: Other. Main funding source(s): British Heart Foundation (BHF) 4-Year PhD Programme Background Insulin-like growth factor binding protein (IGFBP)-1 has previously been shown to be associated with reduced type 2 diabetes (T2D) progression and preferable cardiovascular profiles in patients. Our laboratory previously demonstrated that IGFBP-1 is an insulin sensitiser in mouse models, in addition to having favourable vascular effects, independently of IGFs. IGFBP-1 has an Arg-Gly-Asp (RGD) domain which is thought to facilitate the direct interaction with the heterodimeric cell-surface receptor, integrin α5β1, inducing downstream cell signalling. We then showed the positive effects of IGFBP-1 could be mimicked with an RGD-containing linear peptide, GRGDTP, however this peptide is not a suitable therapeutic as it is rapidly metabolised in vivo. To our knowledge, RGD-based therapeutics have not been explored for cardiometabolic disease. Purpose There are currently few therapeutics which have been specifically designed to address both insulin resistance and the high risk of macrovascular disease in T2D. Therefore, exploring RGD-based integrin agonists will be essential in developing new insulin sensitising therapeutics which prevent cardiovascular complications. Methods The ROCS high speed ligand-based virtual screening tool was used to screen commercially available small molecule libraries mimicking the chemical structure of the RGD sequence of IGFBP-1. Additionally, we performed in silico modelling to predict the binding interactions of these molecules with the integrin α5β1 headpiece to select candidates. We then used a LIVE/DEAD cell viability assay to initially profile any cytotoxic effects of our selected compounds in integrin-expressing human umbilical vein endothelial cells (HUVECs) and C2C12 skeletal muscle myotubes. We further assessed the effects of compounds on relevant HUVEC functions using a high-throughput wound closure assay. Results The structure of the RGD domain of IGFBP-1 can be mimicked with small molecules containing amino acid moieties. These molecules are predicted to bind with micromolar affinity to the integrin, promoting beneficial interactions for integrin agonism. We selected 17 structurally diverse small molecules with the best predicted binding interactions. Initial in vitro profiling demonstrates that the molecules are not cytotoxic. In preliminary analyses, three of the selected compounds show a trend towards inhibition of HUVEC migration and proliferation, while six show a trend towards increased migration and proliferation. Conclusion The RGD domain of IGFBP-1 can be mimicked with novel small molecules, of which we have selected 17 ligands. Our compounds do not affect cell viability in relevant cell types, so can be further profiled. Our initial findings indicate that the compounds have different functional effects on HUVECs which allows us to prioritise hits having favourable effects in the context of T2D, such as enhancing angiogenic properties of endothelial cells.

What problem does this paper attempt to address?

This paper aims to solve the problem of how to mimic the favorable effects of the RGD domain in insulin - like growth factor - binding protein - 1 (IGFBP - 1) by discovering new small - molecule integrin agonists for the treatment of cardiometabolic diseases. Specifically, the researchers focus on developing treatment methods that can simultaneously improve insulin resistance and reduce the risk of cardiovascular diseases in patients with type 2 diabetes (T2D). Currently, there are limited drug options for effective treatment of these two symptoms simultaneously. Therefore, exploring RGD - based integrin agonists is of great significance for developing new insulin - sensitizing drugs and preventing cardiovascular complications. The research background indicates that IGFBP - 1 is associated with reducing the risk of type 2 diabetes (T2D) progression and better cardiovascular conditions in patients. Previous laboratory studies have shown that IGFBP - 1 acts as an insulin - sensitizing agent in mouse models and has favorable vascular effects in addition to its IGF - independent actions. The Arg - Gly - Asp (RGD) domain in IGFBP - 1 is thought to promote its direct interaction with the heterodimer of the cell - surface receptor integrin α5β1, thereby inducing downstream cell signaling. The researchers further demonstrated that the linear peptide GRGDTP containing RGD can mimic the positive effects of IGFBP - 1, but this peptide is not suitable as a therapeutic drug because it is rapidly metabolized in vivo. To the best of the authors' knowledge, RGD - based treatment methods have not been explored for cardiometabolic diseases. To achieve this goal, the research team used the ROCS high - throughput ligand - based virtual screening tool to screen compounds from commercially available small - molecule libraries that can mimic the chemical structure of the RGD sequence in IGFBP - 1. In addition, they also performed computer simulations to predict the interactions of these molecules with the integrin α5β1 head to select candidate compounds. Subsequently, the researchers initially evaluated the cytotoxicity of the selected compounds in human umbilical vein endothelial cells (HUVECs) expressing integrin and C2C12 skeletal muscle myotubes using the LIVE/DEAD cell viability assay. At the same time, they also evaluated the effects of the compounds on relevant HUVEC functions through high - throughput wound - closure assays. The research results show that the structure of the RGD domain in IGFBP - 1 can be mimicked by small molecules containing amino acid moieties. These molecules are expected to bind to integrin with micromolar affinity and promote interactions favorable for integrin agonism. The researchers selected 17 structurally diverse small molecules with the best - predicted binding interactions. Preliminary in vitro analysis showed that these molecules are not cytotoxic. In the preliminary analysis, three selected compounds showed a trend of inhibiting HUVEC migration and proliferation, while six showed a trend of increasing migration and proliferation. In conclusion, the study demonstrated that the RGD domain of IGFBP - 1 can be mimicked by new small molecules, and 17 ligands were selected from them. These compounds do not affect cell viability in relevant cell types and can therefore be further evaluated. Preliminary results indicate that the compounds have different functional effects on HUVECs, which enables the researchers to prioritize "hit" compounds with favorable effects in the context of T2D, such as enhancing the angiogenic properties of endothelial cells.

Identifying novel small molecule integrin agonists to mimic the favourable effects of the RGD domain of IGFBP-1 to treat cardiometabolic disease

A Novel Angiogenesis Role of GLP-1(32-36) to Rescue Diabetic Ischemic Lower Limbs Via GLP-1R-Dependent Glycolysis

AI Screening and Molecular Dynamic Simulation-Driven Identification of Novel Inhibitors of TGFßR1 for Pancreatic Cancer Therapy

Identification of potential drug candidates as TGR5 agonist to combat type II diabetes using in silico docking and molecular dynamics simulation studies

Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists

FRI017 Precision-engineered Activin And GDF Ligand Trap HS235: A Novel Lean Mass-preserving Treatment for Obesity

De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8

Targeting GLP-1 receptor trafficking to improve agonist efficacy

Functional screening and rational design of compounds targeting GPR132 to treat diabetes

Developing 2-Aminothiophene Derivatives as Positive Allosteric Modulators of Glucagon-Like Peptide 1 Receptor

Identification of Insulin-Mimetic Plant Extracts: From an In Vitro High-Content Screen to Blood Glucose Reduction in Live Animals

Novel Angiogenesis Role of GLP-1(32–36) to Rescue Diabetic Ischemic Lower Limbs via GLP-1R–Dependent Glycolysis in Mice

Molecular basis of enhanced GLP-1 signaling mediated by GLP-1(9-36) in conjunction with LSN3318839

298-OR: Precision-Engineered Activin and GDF Ligand Trap HS235—A Novel Lean Mass–Preserving Treatment for Obesity

Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity

In silico screening of potential agonists of a glucagon-like peptide-1 receptor among female sex hormone derivatives

Potential off-target effects of beta-blockers on gut hormone receptors: In silico study including GUT-DOCK—A web service for small-molecule docking

Establishment of Platform for Screening Insulin-Like Growth Factor-1 Receptor Inhibitors and Evaluation of Novel Inhibitors

Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor